| Segment P&L (Unaudited) | ||||||||||||||||||||||||
|
|
Materialise | Materialise | Materialise | Total | Adjustments & | |||||||||||||||||||
|
In thousands euros |
Software | Medical | Manufacturing | segments | eliminations | Consolidated | ||||||||||||||||||
| For the three month period ended 31 December 2016 | ||||||||||||||||||||||||
| Revenues | 8,078 | 10,061 | 13,326 | 31,465 | 12 | 31,477 | ||||||||||||||||||
| Segment EBITDA | 2,949 | 656 | 1,438 | 5,043 | (848 | ) | 4,195 | |||||||||||||||||
| Segment EBITDA % | 36.5 | % | 6.5 | % | 10.8 | % | 16.0 | % | 13.3 | % | ||||||||||||||
| For the three month period ended 31 December 2015 | ||||||||||||||||||||||||
| Revenues | 7,301 | 9,570 | 11,161 | 28,032 | - | 28,032 | ||||||||||||||||||
| Segment EBITDA | 2,706 | 747 | 1,033 | 4,486 | (1,621 | ) | 2,865 | |||||||||||||||||
| Segment EBITDA % | 37.1 | % | 7.8 | % | 9.3 | % | 16.0 | % | 10.2 | % | ||||||||||||||
| For the twelve month period ended 31 December 2016 | ||||||||||||||||||||||||
| Revenues | 30,122 | 37,910 | 46,406 | 114,438 | 39 | 114,477 | ||||||||||||||||||
| Segment EBITDA | 10,130 | 894 | 3,848 | 14,872 | (6,391 | ) | 8,481 | |||||||||||||||||
| Segment EBITDA % | 33.6 | % | 2.4 | % | 8.3 | % | 13.0 | % | 7.4 | % | ||||||||||||||
| For the twelve month period ended 31 December 2015 | ||||||||||||||||||||||||
| Revenues | 25,798 | 34,856 | 41,381 | 102,035 | - | 102,035 | ||||||||||||||||||
| Segment EBITDA | 9,093 | 422 | 1,645 | 11,160 | (8,239 | ) | 2,921 | |||||||||||||||||
| Segment EBITDA % | 35.2 | % | 1.2 | % | 4.0 | % | 10.9 | % | 2.9 | % | ||||||||||||||
|
Reconciliation of Net Profit/(Loss) to Segment EBITDA (Unaudited) |
||||||||||||
| (in thousands of euros) | For the three months ended December 31 | For the twelve months ended December 31 | ||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||
| Net profit/(loss) | 620 | 2,145 | -3,019 | -2,860 | ||||||||
| Income taxes | 898 | -1,010 | 1,710 | -389 | ||||||||
| Finance costs | 749 | 362 | 2,437 | 2,470 | ||||||||
| Finance income | -1,002 | -718 | -2,039 | -3,511 | ||||||||
| Share in loss of joint venture | 650 | 153 | 1,018 | 401 | ||||||||
| Operating profit | 1,915 | 932 | 107 | -3,889 | ||||||||
| Depreciation & amortization | 2,280 | 1,933 | 8,374 | 6,810 | ||||||||
| Corporate research and development | 472 | 784 | 1,673 | 2,955 | ||||||||
| Corporate headquarter costs | 1,781 | 2,027 | 8,646 | 9,700 | ||||||||
| Other operating income (expense) | -1,405 | -1,190 | -3,928 | -4,416 | ||||||||
| Segment EBITDA | 5,043 | 4,486 | 14,872 | 11,160 | ||||||||
